부인과 악성종양환자에서 항암화학요법후의 호중구감소에 대한 rhG-CSF ( Neutrogin 주 ) 의 임상효과 = Clinical Effects of Recombinant Human G-CSF ( Neutrogin ) on Neutropenia Induced by the Cancer Chemotherapy for Gynecologic Malignancy

다국어 초록 (Multilingual Abstract)

This study is undertaken to investigate the clinical effects of Neutrogin (recombinant human granulocyte-colony stimulating factor) in 25 patients with ovarina cancer and endometrial cancer who received two courses of CAP chemotherapy. In the first course of chemotherapy as a control course, all patients were treated with CAP chemotherapy alone and during the second course, Neutrogin was given at a dose of 2 micro g/kg/day subcutaneously for 14 days 24 hours after completion of chemotherapy. Neutrogin significantly increased the nadir count of leukocyte and absolute neutrophil and decreased the number of days per patient on which the absolute neutrophil count was 1,000/mm^3 or less. The mean recovery time required for neutrophil to greater than 1,500/mm^3 after nadir were significantly decreased in the second course as compared with the first course. Each one patient experienced mild side effects of Neutrogin, such as fever, bone pain and malaise and recovered without treatment. These results were showed that Neutrogin was extremely effective and useful to treat chemotherapy indeced leukopenia and to accelerate the recovery from these complications.